Jury Says BGI Owes Illumina $8M For Infringing DNA Patents
By Hannah Albarazi (November 30, 2021, 11:16 PM EST) -- A California federal jury determined Tuesday that four out of five of Illumina's patents behind its next-generation genome-sequencing technology were valid, finding that Illumina's Chinese rival BGI Genomics and its subsidiaries willfully infringed the patents and must pay Illumina $8 million in damages, according to a person familiar with the case.
After about a week of deliberations, the jury determined that BGI — China's largest provider of sequencing services — willfully infringed Illumina's patents, while also determining that Illumina's U.S. Patent No. 7,541,444 is invalid as obvious, the source said.
Illumina, in an emailed statement to Law360 on Wednesday, said the company is "pleased that...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!